Streetbeat News

Revenues

HGTY

Hagerty has reaffirmed its 2024 financial outlook, projecting significant growth across key financial metrics. The company expects total revenue growth of 15%-17%, net income growth of 116%-148%, and adjusted EBITDA growth of 41%-53%.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:49 am

GBTG

Global Business Travel Group (GBTG) has reiterated its FY24 revenue guidance of $2.43B-$2.5B, aligning with expectations and aiming for strong profitability growth. The forecast includes an 18%-32% increase in Adjusted EBITDA and over $100M in Free Cash Flow, excluding impacts from the CWT acquisition expected to close in H2 2024.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:49 am

CALM

MO

WBA

Wall Street's most accurate analysts have provided their views on three high-yielding consumer staples stocks: Cal-Maine Foods, Inc. (CALM), Altria Group, Inc. (MO), and Walgreens Boots Alliance, Inc. (WBA). These stocks offer dividend yields of 3.30%, 9.01%, and 5.79% respectively. Recent updates include a retirement announcement from Cal-Maine Foods, a sales decline report from Altria Group, and a new collaboration between DoorDash and Walgreens.

Portfolio Pulse from Avi Kapoor

May 07, 2024 | 11:49 am

CTV

Innovid has updated its Q2 revenue forecast to $37.5M-$39.5M, slightly above the estimated $38.3M, and raised its FY24 revenue outlook from $154M-$162M to $156M-$163M, surpassing the estimated $158.294M. The company also increased its FY 2024 Adjusted EBITDA forecast from $22M-$28M to $24M-$29M, indicating expectations for continued revenue growth and margin expansion.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:45 am

SOPH

SOPHiA GENETICS has reaffirmed its fiscal year 2024 revenue guidance to be in the range of $78 million to $81 million, aligning closely with the analyst estimate of $79.168 million.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:44 am

HLMN

Hillman Solutions reaffirmed its full year 2024 revenue guidance of $1.475B-$1.555B, aligning with market expectations of $1.514B. The company also expects free cash flow to be between $100M-$120M, based on its performance outlook for the year ending December 28, 2024. This guidance, initially provided on February 22, 2024, alongside Q4 2023 results, reflects Hillman's current market view and performance expectations.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:44 am

STIM

Neuronetics projects its Q2 total worldwide revenue to be between $18.0M-$19.0M, falling short of the $19.47M estimate. For FY24, the company anticipates revenue between $78M-$80M, aligning closely with the $79.13M estimate.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:41 am

VVX

V2X has reaffirmed its 2024 financial guidance, projecting revenues between $4.10B-$4.20B, which aligns with the estimated $4.152B, and an adjusted EPS range of $3.85-$4.20, significantly higher than the $1.08 estimate. The company's leadership expressed satisfaction with its operational performance and the successful integration of new programs.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:39 am

ML

MoneyLion expects Q2 2024 revenue to be between $125M-$130M, indicating a 17-22% growth compared to Q2 2023. The company also forecasts an Adjusted EBITDA of $17M-$20M, which would represent a margin of 13.1-16.0%, significantly higher than the 8.7% margin in Q2 2023.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:37 am

EHTH

eHealth projects its FY24 revenue to be between $450M and $475M, which is in line with the analyst estimate of $461.68M.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:36 am